Orchid to market Cefadroxil in US

Orchid says it has received nod for marketing in the US Cefadroxil dosages of 500 mg in capsule form and 1 g in tablet form.

Orchid Chemicals and Pharmaceuticals Ltd on Friday said it has received approval from the USFDA for its Cefadroxil abbreviated new drug applications.

HT Image

In a filing on the Bombay Stock Exchange, the company said it had received the formal nod for dosages of 500 mg in capsule form and 1 g in tablet form.

Cefadroxil is a cephalosporin-type antibiotic used to treat a wide variety of bacterial infections.

The company said it would launch the oral cephalosporin product in the US through its distribution partner, Par Pharma.

Following this approval, the company's ANDAs approved till date has risen to 17, Orchid said.